1. Chlorinated benzothiadiazines inhibit angiogenesis through suppression of VEGFR2 phosphorylation.
- Author
-
Huwaimel BI, Jonnalagadda S, Jonnalagadda S, Zahra FT, Nocentini A, Supuran CT, Mikelis CM, and Trippier PC
- Subjects
- Angiogenesis Inhibitors pharmacology, Cell Movement, Cell Proliferation, Human Umbilical Vein Endothelial Cells metabolism, Humans, Neovascularization, Pathologic drug therapy, Phosphorylation, Protein-Tyrosine Kinases metabolism, Vascular Endothelial Growth Factor Receptor-2, Benzothiadiazines metabolism, Benzothiadiazines pharmacology, Vascular Endothelial Growth Factor A metabolism
- Abstract
Angiogenesis inhibitors are a critical pharmacological tool for the treatment of solid tumors. Suppressing vascular permeability leads to inhibition of tumor growth, invasion, and metastatic potential by blocking the supply of oxygen and nutrients. Disruption of the vascular endothelial growth factor (VEGF) signaling pathway is a validated target for the design of antiangiogenic agents. Several VEGFR2 inhibitors have been clinically approved over the past years. Structural analysis of these clinical VEGFR2 inhibitors highlighted key functional group overlap with the benzothiadiazine core contained in a library of in-house compounds. Herein we ascribe anti-angiogenic activity to a series of chlorinated benzothiadiazines. Selected compounds show significant activity to completely ameliorate VEGF-induced endothelial cell proliferation by suppression of VEGFR2 phosphorylation. The scaffold is devoid of activity to inhibit carbonic anhydrases and generally lacks cytotoxicity across a range of cancer and non-malignant cell lines. Assay of activity at 468 kinases shows remarkable selectivity with only four kinases inhibited > 65% at 10 µM concentration, and with significant activity to inhibit TNK2/ACK1 and PKRD2 by > 90%. All four identified kinase targets are known modulators of angiogenesis, thus highlighting compound 17b as a novel angiogenesis inhibitor for further development., (Copyright © 2022 Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF